Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (DRKS00041540) titled 'Real-World Evaluation of ¹77Lu-PSMA Radioligand Therapy (¹77Lu-PSMA-RLT) as First-Line Treatment for Metastatic Castration-Resistant Prostate Cancer' on Sept. 7.
Study Type: observational
Study Design:
Allocation:
Masking:
Control:
Assignment:
Study design purpose: treatment
Primary Sponsor: Universitatsklinikum Augsburg, Klinik fur Urologie
Condition:
C61
Malignant neoplasm of prostate
Intervention:
Group 1: Patients with metastatic castration-resistant prostate cancer (mCRPC) receiving ¹77Lu-PSMA radioligand therapy as first-line treatment.
Non-profit, non-interventional, multicenter, nation...